First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis.

CONCLUSION: Substituting fulvestrant as a first-line therapy for hormone-receptor-positive metastatic breast cancer is not cost-effective compared with anastrozole based on the willing-to-pay threshold of $150,000 per QALY. PMID: 31853795 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31853795?dopt=Abstract

Source: Breast Cancer - December 17, 2019 Category: Cancer & Oncology Authors: Liao W, Huang J, Wu Q, Wen F, Zhang N, Zhou K, Bai L, Li Q Tags: Breast Cancer Source Type: research